Bob Hugin “slashed price for cancer drug in Russia while raising it here.”
— NJ.COM, Aug 5, 2018
Bob Hugin made hundreds of millions price-gouging cancer patients over the years. Now NJ.com is reporting that Bob Hugin’s company, Celgene, raised prices on American cancer patients while giving huge discounts to Russia.
Celgene Corp. under Bob Hugin, the Republican running for U.S. Senate in New Jersey, raised U.S. prices by 20 percent for its Revlimid cancer drug while cutting them by 45 percent in Russia last year, documents show…
Celgene under Hugin spent a record amount of money to help defeat legislation that would have made it easier for generic companies to get drug samples, and President Donald Trump‘s Food and Drug Administration singled out the company for refusing to make those samples available to competitors.
Celgene’s pricing of the cancer drug Revlimid has come under attack by Trump and advocacy groups.
The price of a 21-tablet supply of Revlimid in 25 mg dose was $14,529 in the United States, according to a report by Patients for Affordable Drugs Action, a super political action committee opposing Hugin.
That same product cost $4,175 in Russia after the price reduction, according to the Russian Federation’s Federal Antimonopoly Service.
New Jersey can’t afford to have Bob Hugin in Washington, D.C. working for Donald Trump, Vladimir Putin, and the pharmaceutical industry instead of working families.